Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Shigeru Horiguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9769-8262; OpenAlex author ID A5083635614. Sources: OpenAlex.

Their work

Papers
21
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: none · 2016: 2 papers · 2017: 1 paper · 2018: 1 paper · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 1 paper

Papers 21

  1. Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/cas.70533↗
  2. A case of pancreatic ductal adenocarcinoma growing within the pancreatic duct mimicking an intraductal tubulopapillary neoplasm. Co-author DOI 10.1007/s12328-025-02098-y↗
  3. Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers17203287↗
  4. Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Co-author DOI 10.7759/cureus.79001↗
  5. Correction: Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. Co-author DOI 10.7759/cureus.c365↗
  6. Association of screening tool scores with overall survival in older patients with unresectable gastrointestinal or biliary pancreatic cancer: A retrospective s… Co-author DOI 10.1016/j.jgo.2024.101714↗
  7. Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding. Co-author DOI 10.1016/j.pan.2023.10.018↗
  8. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.18926/amo/65974↗
  9. Effectiveness of an Oral Elemental Diet for Patients With Unresectable Pancreatic Cancer: a Prospective Cohort Study Co-author DOI 10.21203/rs.3.rs-1244457/v1↗
  10. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer. Co-author DOI 10.1080/15384047.2021.1980312↗
  11. Evaluation of Local Recurrence of Pancreatic Cancer by KRAS Mutation Analysis Using Washes from Endoscopic Ultrasound-Guided Fine-Needle Aspiration. Co-author DOI 10.1007/s10620-019-06006-6↗
  12. The relationship between the PD-L1 expression of surgically resected and fine-needle aspiration specimens for patients with pancreatic cancer. Co-author DOI 10.1007/s00535-019-01586-6↗
  13. Utility of liquid biopsy using urine in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/15384047.2019.1638685↗
  14. Diagnostic Ability of Convex-Arrayed Endoscopic Ultrasonography for Major Vascular Invasion in Pancreatic Cancer. Co-author DOI 10.5946/ce.2018.163↗
  15. Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cance… Co-author DOI 10.1186/s12876-018-0886-8↗
  16. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Co-author DOI 10.1016/j.pan.2016.12.011↗
  17. Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer. Co-author DOI 10.1038/cgt.2016.31↗
  18. Synergistic anti-pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf-3 protein and peripheral blood mon… Co-author DOI 10.1111/jgh.13259↗
  19. Corrigendum to “Loss of runt‐related transcription factor 3 induces gemcitabine resistance in pancreatic cancer” [Mol. Oncol. 7 (2013) 840–849] Co-author DOI 10.1016/j.molonc.2014.03.007↗
  20. Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer. Co-author DOI 10.1111/jgh.12501↗
  21. Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2013.04.004↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hironari Kato · 18 shared papers, 2013–2025 · strength 1.94
  2. Kazuyuki Matsumoto · 13 shared papers, 2017–2025 · strength 1.90
  3. Motoyuki Otsuka · 7 shared papers, 2023–2026 · strength 1.52
  4. Yuki Fujii · 6 shared papers, 2019–2026 · strength 1.13
  5. Daisuke Uchida · 11 shared papers, 2014–2026 · strength 1.01
  6. Koichiro Tsutsumi · 6 shared papers, 2017–2026 · strength 0.93
  7. Ryosuke Sato · 4 shared papers, 2022–2025 · strength 0.89
  8. Hiroyuki Terasawa · 5 shared papers, 2019–2026 · strength 0.74
  9. Kosei Takagi · 3 shared papers, 2025–2026 · strength 0.71
  10. Hiroyuki Okada · 6 shared papers, 2019–2024 · strength 0.68
  11. Soichiro Ako · 5 shared papers, 2017–2026 · strength 0.57
  12. Hideaki Kinugasa · 5 shared papers, 2017–2026 · strength 0.57
  13. Kazuhiro Nouso · 9 shared papers, 2013–2021 · strength 0.55
  14. Kazuya Yasui · 2 shared papers, 2025–2026 · strength 0.47
  15. Shinichiro Muro · 5 shared papers, 2017–2021 · strength 0.42
  16. Tatsuya Kikuchi · 2 shared papers, 2023–2026 · strength 0.36
  17. Yasuo Nagai · 1 shared paper, 2025 · strength 0.25
  18. Takeyoshi Nishiyama · 1 shared paper, 2025 · strength 0.25
  19. Toshiyoshi Fujiwara · 1 shared paper, 2025 · strength 0.25
  20. Yuzo Umeda · 2 shared papers, 2019–2021 · strength 0.18
  21. Ryuichi Yoshida · 2 shared papers, 2019–2021 · strength 0.18
  22. Hiroyuki Okada · 2 shared papers, 2018–2021 · strength 0.18
  23. Shoko Inoo · 1 shared paper, 2024 · strength 0.17
  24. Kazuhide Yamamoto · 4 shared papers, 2013–2016 · strength 0.15
  25. Hitomi Himei · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.